Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
SWAV

SWAV - Shockwave Medical Inc Stock Price, Fair Value and News

334.75USD Market Closed

Market Summary

SWAV
USD334.75
Market Closed

SWAV Alerts

  • Big jump in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)

SWAV Stock Price

View Fullscreen

SWAV RSI Chart

SWAV Valuation

Market Cap

12.6B

Price/Earnings (Trailing)

76.87

Price/Sales (Trailing)

15.95

EV/EBITDA

63.66

Price/Free Cashflow

75.65

SWAV Price/Sales (Trailing)

SWAV Profitability

EBT Margin

23.29%

Return on Equity

21.75%

Return on Assets

9.95%

Free Cashflow Yield

1.32%

SWAV Fundamentals

SWAV Revenue

Revenue (TTM)

788.0M

Rev. Growth (Yr)

35.85%

Rev. Growth (Qtr)

7.8%

SWAV Earnings

Earnings (TTM)

163.5M

Earnings Growth (Yr)

41.46%

Earnings Growth (Qtr)

24.92%

Breaking Down SWAV Revenue

Last 7 days

0.2%

Last 30 days

1.5%

Last 90 days

27.1%

Trailing 12 Months

18.9%

How does SWAV drawdown profile look like?

SWAV Financial Health

Current Ratio

13.81

Debt/Equity

0.97

Debt/Cashflow

0.27

SWAV Investor Care

Shares Dilution (1Y)

2.50%

Diluted EPS (TTM)

4.26

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024788.0M000
2023557.2M616.6M671.3M730.2M
2022298.9M363.7M429.9M489.7M
202184.5M130.1M175.7M237.1M
202050.9M51.1M59.4M67.8M
201918.2M25.9M33.7M42.9M
20184.4M7.0M9.6M12.3M
20170001.7M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Shockwave Medical Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 31, 2024
gaeta renee
back to issuer
-
-
-19,890
chief financial officer
May 31, 2024
watkins frank t
back to issuer
-
-
-4,532
-
May 31, 2024
toyloy sara
back to issuer
-
-
-3,673
-
May 31, 2024
phung trinh
back to issuer
-
-
-50,387
svp, finance
May 31, 2024
moll frederic h
back to issuer
-
-
-287,521
-
May 31, 2024
papiernik antoine
back to issuer
-
-
-736
-
May 31, 2024
zacharias isaac
back to issuer
-
-
-56,288
president, cco
May 31, 2024
papiernik antoine
back to issuer
-
-
-34,177
-
May 31, 2024
francis laura
back to issuer
-
-
-1,233
-
May 31, 2024
francis laura
back to issuer
-
-
-3,551
-

1–10 of 50

Which funds bought or sold SWAV recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 11, 2024
EverSource Wealth Advisors, LLC
added
5.93
21,491
47,217
-%
Jun 04, 2024
DekaBank Deutsche Girozentrale
reduced
-37.25
8,000
131,000
-%
Jun 04, 2024
Tactive Advisors, LLC
new
-
260,504
260,504
0.14%
May 28, 2024
Verity Asset Management, Inc.
reduced
-4.99
618,781
1,611,220
0.90%
May 28, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
1,596,000
3,847,000
0.03%
May 24, 2024
Cetera Investment Advisers
new
-
3,220,480
3,220,480
0.01%
May 22, 2024
Beck Bode, LLC
added
8.47
4,947,930
10,745,200
2.19%
May 21, 2024
APEIRON CAPITAL Ltd
reduced
-52.46
-654,267
2,832,980
1.43%
May 16, 2024
Virtus Investment Advisers, Inc.
reduced
-56.85
-46,754
131,229
0.09%
May 16, 2024
Motley Fool Asset Management LLC
reduced
-2.89
8,016,970
20,176,000
1.30%

1–10 of 38

Are Funds Buying or Selling SWAV?

Are funds buying SWAV calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own SWAV
No. of Funds

Unveiling Shockwave Medical Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
9.85%
3,633,720
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Feb 08, 2024
wellington management group llp
6.78%
2,500,594
SC 13G
Jan 24, 2024
blackrock inc.
10.1%
3,740,596
SC 13G/A
Feb 14, 2023
price t rowe associates inc /md/
2.8%
1,012,393
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Jan 23, 2023
blackrock inc.
12.7%
4,572,659
SC 13G/A
Jan 10, 2023
vanguard group inc
10.22%
3,694,931
SC 13G/A
Jul 08, 2022
blackrock inc.
12.1%
4,313,553
SC 13G
Feb 14, 2022
price t rowe associates inc /md/
8.7%
3,077,252
SC 13G/A

Recent SEC filings of Shockwave Medical Inc

View All Filings
Date Filed Form Type Document
Jun 10, 2024
15-12G
15-12G
May 31, 2024
S-8 POS
Employee Benefits Plan
May 31, 2024
S-8 POS
Employee Benefits Plan
May 31, 2024
S-8 POS
Employee Benefits Plan
May 31, 2024
S-8 POS
Employee Benefits Plan
May 31, 2024
S-8 POS
Employee Benefits Plan
May 31, 2024
S-8 POS
Employee Benefits Plan
May 31, 2024
POSASR
POSASR
May 31, 2024
8-K
Current Report
May 31, 2024
4
Insider Trading

Peers (Alternatives to Shockwave Medical Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
181.0B
40.3B
-0.10% -2.08%
32.14
4.49
-2.84% -3.00%
67.5B
19.7B
-1.09% -9.63%
50.67
3.43
4.82% -17.56%
18.2B
3.9B
-10.79% -26.67%
39.44
4.66
5.72% 46.72%
17.2B
14.9B
-4.31% -25.64%
6.49
1.15
2.98% 207.68%
MID-CAP
9.7B
3.5B
-0.66% 25.22%
31.07
2.74
6.16% 35.06%
8.7B
12.4B
-8.47% -12.48%
22.53
0.7
-0.93% -18.83%
8.2B
2.6B
-1.65% -23.26%
-25.56
3.16
-6.25% -68.58%
5.3B
3.9B
-9.26% -35.41%
-55.79
1.35
0.23% 90.80%
3.4B
387.1M
-0.06% 30.91%
-216.17
8.9
30.82% 65.57%
2.2B
6.6B
-1.48% -10.95%
12.01
0.34
1.50% -10.29%
SMALL-CAP
1.5B
3.2B
12.63% 11.29%
-2.15
0.46
7.94% -1695.32%
384.5M
169.3M
2.09% -2.41%
-5
2.27
7.49% -244.90%
226.3M
324.0M
-6.46% -49.01%
-1.18
0.7
-3.19% -337.41%
47.1M
50.5M
-15.00% -80.46%
-2.07
0.93
14.25% -10.06%
1.8M
3.7M
70.00% -81.62%
-0.15
0.48
5.77% 8.23%

Shockwave Medical Inc News

Latest updates
Defense World17 hours ago
Yahoo Finance30 May 202407:00 am

Shockwave Medical Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue7.8%21920318618016114413112194.0084.0065.0056.0032.0023.0020.0010.0015.0014.0011.0010.007.00
Gross Profit7.3%19117816215614012711310481.0072.0054.0046.0024.0016.0014.007.0010.009.007.006.004.00
Costs and Expenses10.3%14813411812310084.0077.0074.0065.0058.0051.0046.0041.0032.0027.0025.0029.0013.0024.0021.0019.00
Operating Expenses---------------27.0025.0029.00-20.0017.0016.00
  S&GA Expenses10.9%74.0067.0057.0057.0054.0043.0042.0041.0036.0033.0028.0026.0024.0016.0014.0011.0010.0010.008.007.006.00
  R&D Expenses5.1%44.0042.0040.0037.0027.0024.0020.0021.0017.0015.0014.0012.0010.009.008.008.0012.0010.008.007.007.00
EBITDA Margin-1.1%0.26*0.26*0.26*0.26*0.28*0.26*0.22*0.17*0.11*-0.02*-0.19*-0.38*---------
Interest Expenses-0.2%3.003.003.001.001.001.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00
Income Taxes-147.5%-5.3011.0010.004.002.00-96.250.001.000.000.000.000.000.000.000.000.000.000.000.000.000.00
Earnings Before Taxes-9.8%50.0055.0045.0033.0041.0045.0035.0026.0015.0013.002.00-0.35-23.56-15.87-12.90-18.10-18.75-14.73-12.93-10.59-12.79
EBT Margin-2.4%0.23*0.24*0.24*0.25*0.26*0.25*0.21*0.15*0.10*-0.04*-0.21*-0.40*---------
Net Income24.9%55.0044.0035.0029.0039.0014135.0026.0015.0013.002.00-0.42-23.60-15.87-12.93-18.12-18.77-14.74-12.96-10.61-12.80
Net Income Margin2.9%0.21*0.20*0.36*0.40*0.43*0.44*0.20*0.15*0.10*-0.04*-0.22*-0.41*---------
Free Cashflow-56.8%27.0064.0044.0031.0027.0041.0027.0025.00-1.3518.006.00-0.52---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets4.9%1,6441,5671,474787783646476417373346299276269272281287221232138147158
  Current Assets4.1%1,2751,2251,129456591459395352310286256240233246258264198217131141152
    Cash Equivalents-14.2%28232849814128115812810066.0091.0093.0086.0058.0052.0021521812314039.0042.00138
  Inventory3.4%11110897.0092.0083.0075.0069.0060.0053.0043.0039.0036.0034.0030.0029.0023.0016.0012.009.008.007.00
  Net PPE14.2%79.0069.0062.0060.0054.0048.0039.0032.0028.0024.0023.0021.0020.0016.0013.0013.0013.005.004.003.003.00
  Goodwill0%40.0040.0040.0040.0040.00----------------
Liabilities-0.7%89289887317021313512011210510479.0068.0065.0046.0044.0042.0043.0039.0030.0027.0028.00
  Current Liabilities-11.4%92.0010478.0080.0014263.0054.0066.0051.0052.0040.0036.0033.0026.0021.0018.0019.0024.0019.0015.0015.00
  Long Term Debt0.1%733732731------------------
    LT Debt, Current----------6.00-----------
    LT Debt, Non Current0.1%733732731------------------
Shareholder's Equity12.4%752669601617571511356305268242220208204226237245178193108119129
  Retained Earnings50.1%16611066.0031.002.00-36.81-177-212-238-252-265-267-267-243-227-214-196-177-163-150-139
  Additional Paid-In Capital5.0%586558535586569549535519507495486476471469465460374371271270269
Shares Outstanding0.8%37.0037.0037.0037.0036.0036.0036.0036.0036.0035.00-34,914---------
Float----7,700-------3,700---4,200---1,000-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-50.0%35,84071,70350,65139,73733,96252,43634,48828,8711,93720,8319,3222,186-17,303-12,399-16,430-18,166-24,189-12,570-10,604-10,518-14,415
  Share Based Compensation5.2%22,93721,81118,41017,04615,96712,64311,73211,0059,5108,2087,3876,5235,1393,2422,8462,3911,8711,3101,106818412
Cashflow From Investing65.1%-84,453-242,262-305,879-83,7686,182-35,276-5,2765,816-27,414-23,102-4,78227,21427,086-153,60712,10629,7034,32516,7917,641-83,555-420
Cashflow From Financing3155.5%5,011-164612,997-95,84183,4099,5963835002,5205002,387-2,138-3,2001,1731,28483,6483,93096,372491-2,067113,256
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

SWAV Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenue:  
Product revenue$ 218,805$ 161,066
Cost of revenue:  
Cost of product revenue28,20721,066
Gross profit190,598140,000
Operating expenses:  
Research and development44,46626,971
Sales and marketing74,49254,011
General and administrative29,23319,204
Total operating expenses148,191100,186
Income from operations42,40739,814
Income (loss) from equity method investment713(823)
Interest and Other Income12,3181,740
Interest expense(2,943)(636)
Other (expense) income, net(2,496)642
Net income before taxes49,99940,737
Income tax expense(5,347)1,612
Net income55,34639,125
Other comprehensive income (loss):  
Unrealized (loss) gain on available-for-sale securities, net of tax(402)505
Net gain reclassified from accumulated other comprehensive income0(5)
Total comprehensive income$ 54,944$ 39,625
Net income per share  
Basic (USD per share)$ 1.48$ 1.07
Diluted (USD per share)$ 1.44$ 1.03
Denominator:  
Basic (in shares)37,284,94636,427,263
Diluted (in shares)38,472,01337,979,448
Type of Revenue [Extensible List]Product [Member]Product [Member]
Type of Cost, Good Or Service [Extensible List]Product [Member]Product [Member]

SWAV Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
CURRENT ASSETS:  
Cash and cash equivalents$ 281,674$ 328,422
Short-term investments747,559662,132
Accounts receivable, net124,440114,552
Inventory111,215107,587
Prepaid expenses and other current assets10,46212,567
Total current assets1,275,3501,225,260
Operating lease right-of-use assets34,91929,707
Property and equipment, net78,69368,923
Equity method investment2,3561,643
Intangible assets, net91,96092,857
Goodwill39,56839,568
Deferred tax assets111,90099,169
Other assets9,0019,436
TOTAL ASSETS1,643,7471,566,563
CURRENT LIABILITIES:  
Accounts payable9,8438,868
Accrued liabilities78,83891,696
Lease liability, current portion3,6533,641
Total current liabilities92,334104,205
Lease liability, noncurrent portion40,33635,103
Convertible Debt, Noncurrent732,810731,863
Related party contract liability, noncurrent portion12,27312,273
Deferred tax liabilities3,6093,609
Other liabilities7,6599,307
TOTAL LIABILITIES891,990897,886
STOCKHOLDERS’ EQUITY:  
Preferred stock00
Common stock3837
Additional paid-in capital586,017557,882
Accumulated other comprehensive (loss) income(109)293
Retained earnings165,811110,465
TOTAL STOCKHOLDERS’ EQUITY751,757668,677
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY1,643,7471,566,563
Long-Term Income Tax Liability$ 2,969$ 1,526
SWAV
ShockWave Medical, Inc., a medical device company, develops intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters for use in our IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter for use in IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.
 CEO
 WEBSITEhttps://shockwavemedical.com
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES1001

Shockwave Medical Inc Frequently Asked Questions


What is the ticker symbol for Shockwave Medical Inc? What does SWAV stand for in stocks?

SWAV is the stock ticker symbol of Shockwave Medical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Shockwave Medical Inc (SWAV)?

As of Fri May 31 2024, market cap of Shockwave Medical Inc is 12.57 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SWAV stock?

You can check SWAV's fair value in chart for subscribers.

What is the fair value of SWAV stock?

You can check SWAV's fair value in chart for subscribers. The fair value of Shockwave Medical Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Shockwave Medical Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SWAV so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Shockwave Medical Inc a good stock to buy?

The fair value guage provides a quick view whether SWAV is over valued or under valued. Whether Shockwave Medical Inc is cheap or expensive depends on the assumptions which impact Shockwave Medical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SWAV.

What is Shockwave Medical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 31 2024, SWAV's PE ratio (Price to Earnings) is 76.87 and Price to Sales (PS) ratio is 15.95. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SWAV PE ratio will change depending on the future growth rate expectations of investors.